相似文献
1
Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
J Clin Microbiol. 2006 Feb;44(2):595-7. doi: 10.1128/JCM.44.2.595-597.2006.
2
Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin.
J Clin Microbiol. 2005 Oct;43(10):5384-7. doi: 10.1128/JCM.43.10.5384-5387.2005.
3
Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
J Clin Microbiol. 2008 Mar;46(3):1132-6. doi: 10.1128/JCM.01844-07. Epub 2008 Jan 16.
4
Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
Diagn Microbiol Infect Dis. 2008 Apr;60(4):437-40. doi: 10.1016/j.diagmicrobio.2007.11.002. Epub 2007 Dec 21.
5
Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus.
J Clin Microbiol. 2005 Oct;43(10):5285-7. doi: 10.1128/JCM.43.10.5285-5287.2005.
6
Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.
Clin Infect Dis. 2005 Apr 1;40(7):1058-60. doi: 10.1086/428616. Epub 2005 Feb 17.
7
In vitro activity of ceftobiprole against meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).
Int J Antimicrob Agents. 2010 Nov;36(5):478-80. doi: 10.1016/j.ijantimicag.2010.07.016. Epub 2010 Sep 16.
8
Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.
N Engl J Med. 1999 Feb 18;340(7):493-501. doi: 10.1056/NEJM199902183400701.
9
Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin.
Ann Pharmacother. 2010 May;44(5):918-21. doi: 10.1345/aph.1M665. Epub 2010 Mar 30.
10
Daptomycin therapy failure in an adolescent with methicillin-resistant Staphylococcus aureus bacteremia.
Pediatr Infect Dis J. 2009 May;28(5):445-7. doi: 10.1097/INF.0b013e3181927891.
引用本文的文献
1
Daptomycin-Loaded Nano-Drug Delivery System Based on Biomimetic Cell Membrane Coating Technology: Preparation, Characterization, and Evaluation.
Pharmaceuticals (Basel). 2025 Aug 6;18(8):1169. doi: 10.3390/ph18081169.
2
Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial.
JAMA. 2025 Aug 13. doi: 10.1001/jama.2025.12543.
3
Genetic Correlates of Synergy Mechanisms of Daptomycin Plus Fosfomycin in Daptomycin-Susceptible and -Resistant Methicillin-Resistant (MRSA).
Microorganisms. 2025 Jun 30;13(7):1532. doi: 10.3390/microorganisms13071532.
4
Anti-Staphy Peptides Rationally Designed from Cry10Aa Bacterial Protein.
ACS Omega. 2024 Jun 19;9(27):29159-29174. doi: 10.1021/acsomega.3c07455. eCollection 2024 Jul 9.
5
Asymmetric total synthesis of polycyclic xanthenes and discovery of a WalK activator active against MRSA.
Nat Commun. 2024 Jul 13;15(1):5879. doi: 10.1038/s41467-024-49629-8.
6
Glycyrrhizic Acid Nanoparticles Subside the Activity of Methicillin-Resistant by Suppressing PBP2a.
Pharmaceuticals (Basel). 2024 May 6;17(5):589. doi: 10.3390/ph17050589.
7
Antibacterial Resistance Patterns Among Common Infections in a Tertiary Care Hospital in Saudi Arabia.
Cureus. 2022 Nov 20;14(11):e31695. doi: 10.7759/cureus.31695. eCollection 2022 Nov.
8
Inhibition of the Quorum Sensing System, Elastase Production and Biofilm Formation in by Psammaplin A and Bisaprasin.
Molecules. 2022 Mar 6;27(5):1721. doi: 10.3390/molecules27051721.
9
Synthesis, Stereochemical Confirmation, and Derivatization of 12(S),16ϵ-Dihydroxycleroda-3,13-dien-15,16-olide, a Clerodane Diterpene That Sensitizes Methicillin-Resistant Staphylococcus aureus to β-Lactam Antibiotics.
Angew Chem Int Ed Engl. 2022 Apr 19;61(17):e202117458. doi: 10.1002/anie.202117458. Epub 2022 Feb 28.
10
Polymyxin and lipopeptide antibiotics: membrane-targeting drugs of last resort.
Microbiology (Reading). 2022 Feb;168(2). doi: 10.1099/mic.0.001136.
本文引用的文献
1
Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact.
J Infect Dis. 2005 Jun 15;191(12):2149-52. doi: 10.1086/430352. Epub 2005 May 5.
2
Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.
Clin Infect Dis. 2005 Apr 1;40(7):1058-60. doi: 10.1086/428616. Epub 2005 Feb 17.
3
Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
J Antimicrob Chemother. 2005 Mar;55(3):283-8. doi: 10.1093/jac/dkh546. Epub 2005 Feb 10.
4
Principles of antimicrobial therapy in the transplant patient.
Transpl Infect Dis. 2004 Sep;6(3):97-100. doi: 10.1111/j.1399-3062.2004.00070.x.
5
Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.
Antimicrob Agents Chemother. 2004 Dec;48(12):4665-72. doi: 10.1128/AAC.48.12.4665-4672.2004.
6
The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.
Clin Infect Dis. 2004 Jun 15;38(12):1673-81. doi: 10.1086/420818. Epub 2004 May 20.
7
Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.
Clin Infect Dis. 2004 Apr 1;38(7):994-1000. doi: 10.1086/383472. Epub 2004 Mar 11.
8
In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Microb Drug Resist. 2003 Winter;9(4):389-93. doi: 10.1089/107662903322762833.
9
Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms.
J Antimicrob Chemother. 2004 Apr;53(4):669-74. doi: 10.1093/jac/dkh143. Epub 2004 Feb 25.
10
Resistance studies with daptomycin.
Antimicrob Agents Chemother. 2001 Jun;45(6):1799-802. doi: 10.1128/AAC.45.6.1799-1802.2001.
Zotero 插件